Xiaoqiu Wu

Xiaoqiu Wu

Auto-generated profile, based on publicly available information

Xiaoqiu Wu

Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2020 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
SNShuaijian Ni
Shuaijian Ni
ZZZhenjian Zhuo
Zhenjian Zhuo
YPYufei Pan
Yufei Pan
YYYuanyuan Yu
Yuanyuan Yu
FLFangfei Li
Fangfei Li
GZGe Zhang
Ge Zhang

11 June 2019 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
XWXiaoqiu Wu
Xiaoqiu Wu
HLHonglin Liu
Honglin Liu
DHDongmei Han
Dongmei Han
BPBo Peng
Bo Peng
HZHui Zhang
Hui Zhang
WTWeihong Tan
Weihong Tan

1 January 2015 in Theranostics
Verified
Journal Article
Open access
XWXiaoqiu Wu
Xiaoqiu Wu
ZZZilong Zhao
Zilong Zhao
HBHuarong Bai
Huarong Bai
TFTing Fu
Ting Fu
CYChao Yang
Chao Yang
WTWeihong Tan
Weihong Tan
In this work, we have developed a truncated DNA aptamer, termed XQ-2d, with high affinity and specificity for pancreatic ductal adenocarcinoma (PDAC). Aptamer XQ-2d selectively binds to PL45 cells with a dissociation constant in the nanomolar range, as determined by its recognition of PL45 tumor cells in mice. Moreover, XQ-2d shows better recognition ratio for 40 tissue sections of clinical PDAC samples (82.5%) compared to the initial cell-SELEX selection library (5%). Therefore, XQ-2d can be considered a promising candidate as a tool for PDAC diagnosis and treatment.

Verified
Journal Article
Open access
PDF file
LWLuyao Wang
Luyao Wang
CLChao Liang
Chao Liang
FLFangfei Li
Fangfei Li
GDGuan Daogang
Guan Daogang
XWXiaoqiu Wu
Xiaoqiu Wu
GZGe Zhang
Ge Zhang
Poly (ADP-ribose) polymerase 1 (PARP1), the best-studied isoform of the nuclear enzyme PARP family, plays a pivotal role in cellular biological processes, such as DNA repair, gene transcription, and so on. PARP1 has been found to be overexpressed in various carcinomas. These all indicate the clinical potential of PARP1 as a therapeutic target of human malignancies. Additionally, multiple preclinical research studies and clinical trials demonstrate that inhibition of PARP1 can repress tumor growth and metastasis. Up until now, PARP1 inhibitors are clinically used not only for monotherapy to suppress various tumors, but also for adjuvant therapy, to maintain or enhance therapeutic effects of mature antineoplastic drugs, as well as protect patients from chemotherapy and surgery-induced injury. To supply a framework for understanding recent research progress of PARP1 in carcinomas, we review the structure, expression, functions, and mechanisms of PARP1, and summarize the clinically mature PARP1-related anticancer agents, to provide some ideas for the development of other promising PARP1 inhibitors in antineoplastic therapy.

11 February 2020 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
XWXiaoqiu Wu
Xiaoqiu Wu
FLFangfei Li
Fangfei Li
LDLei Dang
Lei Dang
CLChao Liang
Chao Liang
ALAiping Lu
Aiping Lu
GZGe Zhang
Ge Zhang
Breast cancer remains one of the most life-threatening tumors affecting women. Most patients with advanced breast cancer eventually develop metastatic diseases, which cause significant morbidity and mortality. Approximately two-thirds of patients with advanced breast cancer exhibit osteolytic-type bone metastasis, which seriously reduce the quality of life. Therefore, development of novel therapeutic strategies for treating breast cancer patients with bone metastasis is urgently required. The “seed and soil” theory, which describes the interaction between the circulating breast cancer cells (seeds) and bone microenvironment (soil), is widely accepted as the mechanism underlying metastasis. Disruption of any step in this cycle might have promising anti-metastasis implications. The interaction of receptor activator of nuclear factor-κB ligand (RANKL) and its receptor RANK is fundamental in this vicious cycle and has been shown to be a novel effective therapeutic target. A series of therapeutic strategies have been developed to intervene in this cross-talk. Therefore, in this review, we have systematically introduced the functions of the RANKL/RANK signaling system in breast cancer and discussed related therapeutic strategies.

10 September 2020 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
MSMeiheng Sun
Meiheng Sun
XWXiaoqiu Wu
Xiaoqiu Wu
YYYuanyuan Yu
Yuanyuan Yu
LWLuyao Wang
Luyao Wang
DXDuoli Xie
Duoli Xie
LFLi Fangfei
Li Fangfei
Since calcium and phosphorus play vital roles in a multitude of physiologic systems, disorders of calcium and phosphorus metabolism always lead to severe consequences such as skeletal-related and cardiovascular morbidity, or even life-threatening. Physiologically, the maintenance of calcium and phosphorus homeostasis is achieved via a variety of concerted actions of hormones such as parathyroid hormone (PTH), vitamin D, and fibroblast growth factor (FGF23), which could be regulated mainly at three organs, the intestine, kidney, and bone. Disruption of any organ or factor might lead to disorders of calcium and phosphorus metabolism. Currently, lacking of accurate diagnostic approaches and unknown molecular basis of pathophysiology will result in patients being unable to receive a precise diagnosis and personalized treatment timely. Therefore, it is urgent to identify early diagnostic biomarkers and develop therapeutic strategies. Fortunately, proteomics and metabolomics offer promising tools to discover novel indicators and further understanding of pathological mechanisms. Therefore, in this review, we will give a systematic introduction on PTH-1,25(OH)2D-FGF23 axis in the disorders of calcium and phosphorus metabolism, diagnostic biomarkers identified, and potential altered metabolic pathways involved.